Effectiveness and safety of abciximab after failed thrombolytic therapy.
Publication
, Journal Article
Cantor, WJ; Kaplan, AL; Velianou, JL; Sketch, MH; Barsness, GW; Berger, PB; Ohman, EM
Published in: Am J Cardiol
February 15, 2001
Among 214 patients treated with abciximab within 24 hours of full-dose thrombolytic therapy, major bleeding occurred in 50 patients (23%; 95% confidence interval [CI] 18% to 30%) and intracranial hemorrhage occurred in 3 patients (1.4%; 95% CI 0.3% to 4%). The independent multivariate predictors of major bleeding were age (odds ratio [OR] 1.53/10 years, 95% CI 1.05 to 2.21, p = 0.03), time from thrombolytic to abciximab (OR 0.91/hour, 95% CI 0.83 to 0.99, p = 0.03), and intra-aortic balloon pump insertion (OR 4.42, 95% CI 2.00 to 9.72, p = 0.0002).
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Am J Cardiol
DOI
ISSN
0002-9149
Publication Date
February 15, 2001
Volume
87
Issue
4
Start / End Page
439 / A4
Location
United States
Related Subject Headings
- Treatment Failure
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Risk Factors
- Recombinant Proteins
- Platelet Aggregation Inhibitors
- Myocardial Ischemia
- Myocardial Infarction
- Middle Aged
- Male
Citation
APA
Chicago
ICMJE
MLA
NLM
Cantor, W. J., Kaplan, A. L., Velianou, J. L., Sketch, M. H., Barsness, G. W., Berger, P. B., & Ohman, E. M. (2001). Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol, 87(4), 439-A4. https://doi.org/10.1016/s0002-9149(00)01398-9
Cantor, W. J., A. L. Kaplan, J. L. Velianou, M. H. Sketch, G. W. Barsness, P. B. Berger, and E. M. Ohman. “Effectiveness and safety of abciximab after failed thrombolytic therapy.” Am J Cardiol 87, no. 4 (February 15, 2001): 439-A4. https://doi.org/10.1016/s0002-9149(00)01398-9.
Cantor WJ, Kaplan AL, Velianou JL, Sketch MH, Barsness GW, Berger PB, et al. Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol. 2001 Feb 15;87(4):439-A4.
Cantor, W. J., et al. “Effectiveness and safety of abciximab after failed thrombolytic therapy.” Am J Cardiol, vol. 87, no. 4, Feb. 2001, pp. 439-A4. Pubmed, doi:10.1016/s0002-9149(00)01398-9.
Cantor WJ, Kaplan AL, Velianou JL, Sketch MH, Barsness GW, Berger PB, Ohman EM. Effectiveness and safety of abciximab after failed thrombolytic therapy. Am J Cardiol. 2001 Feb 15;87(4):439-A4.
Published In
Am J Cardiol
DOI
ISSN
0002-9149
Publication Date
February 15, 2001
Volume
87
Issue
4
Start / End Page
439 / A4
Location
United States
Related Subject Headings
- Treatment Failure
- Tissue Plasminogen Activator
- Thrombolytic Therapy
- Risk Factors
- Recombinant Proteins
- Platelet Aggregation Inhibitors
- Myocardial Ischemia
- Myocardial Infarction
- Middle Aged
- Male